CO2018002421A2 - Formulaciones de pirofosfato férrico sólido soluble - Google Patents

Formulaciones de pirofosfato férrico sólido soluble

Info

Publication number
CO2018002421A2
CO2018002421A2 CONC2018/0002421A CO2018002421A CO2018002421A2 CO 2018002421 A2 CO2018002421 A2 CO 2018002421A2 CO 2018002421 A CO2018002421 A CO 2018002421A CO 2018002421 A2 CO2018002421 A2 CO 2018002421A2
Authority
CO
Colombia
Prior art keywords
ferric pyrophosphate
soluble solid
formulation
solid ferric
formulations
Prior art date
Application number
CONC2018/0002421A
Other languages
English (en)
Inventor
Robert Chioini
Ajay Gupta
Original Assignee
Rockwell Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockwell Medical Inc filed Critical Rockwell Medical Inc
Publication of CO2018002421A2 publication Critical patent/CO2018002421A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A61M1/1654—Dialysates therefor
    • A61M1/1656—Apparatus for preparing dialysates
    • A61M1/1666—Apparatus for preparing dialysates by dissolving solids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
    • A61M1/287—Dialysates therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • External Artificial Organs (AREA)

Abstract

Se proporciona una formulación en forma de partículas sólidas que comprende pirofosfato férrico soluble y una bolsita que comprende la formulación en forma de partículas sólidas de pirofosfato férrico soluble para su adición a una solución de diálisis. También se divulgan métodos mejorados para administrar pirofosfato férrico soluble que comprende las formulaciones de partículas sólidas y los kits que comprenden la formulación en forma de partículas sólidas y una formulación de concentrado para diálisis.
CONC2018/0002421A 2015-09-04 2018-03-02 Formulaciones de pirofosfato férrico sólido soluble CO2018002421A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562214908P 2015-09-04 2015-09-04
PCT/US2016/050120 WO2017040937A1 (en) 2015-09-04 2016-09-02 Solid soluble ferric pyrophosphate formulations, kits, and methods using the same

Publications (1)

Publication Number Publication Date
CO2018002421A2 true CO2018002421A2 (es) 2018-07-19

Family

ID=56926337

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0002421A CO2018002421A2 (es) 2015-09-04 2018-03-02 Formulaciones de pirofosfato férrico sólido soluble

Country Status (17)

Country Link
US (1) US11517555B2 (es)
EP (1) EP3344235A1 (es)
JP (1) JP7055738B2 (es)
KR (1) KR20180050346A (es)
CN (1) CN108601738A (es)
AU (1) AU2016315877B2 (es)
BR (1) BR112018004244A2 (es)
CA (1) CA2997328A1 (es)
CL (1) CL2018000566A1 (es)
CO (1) CO2018002421A2 (es)
EA (1) EA201890642A1 (es)
IL (1) IL257796B (es)
MX (1) MX2018002633A (es)
PE (1) PE20181162A1 (es)
PH (1) PH12018500463A1 (es)
SG (1) SG10202107245UA (es)
WO (1) WO2017040937A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11278651B2 (en) * 2018-10-17 2022-03-22 Gambro Lundia Ab Membrane and device for treating restless leg syndrome
CN110063965A (zh) * 2019-06-04 2019-07-30 吉林省富生医疗器械有限公司 一种血液透析浓缩物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5177068A (en) * 1984-04-19 1993-01-05 National Research Development Corporation Pharmaceutical compositions
US6576264B1 (en) * 1995-10-17 2003-06-10 Skyepharma Canada Inc. Insoluble drug delivery
US6689275B1 (en) 1996-12-31 2004-02-10 Ajay Gupta Method and pharmaceutical composition for replacing iron losses in dialysis patients
US6779468B1 (en) 1997-08-07 2004-08-24 Ajay Gupta Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients
JP3778240B2 (ja) 1998-06-22 2006-05-24 ライオン株式会社 不快な味がマスキングされた造粒組成物及びその製造方法
AU5926999A (en) 1998-09-18 2000-04-10 Rockwell Medical Technologies, Inc. Method and apparatus for preparing liquid dialysate
US6682761B2 (en) * 2000-04-20 2004-01-27 Rtp Pharma, Inc. Water-insoluble drug particle process
WO2002051381A1 (fr) 2000-12-26 2002-07-04 Takeda Chemical Industries, Ltd. Substance poreuse et son procede de fabrication
JP2002302435A (ja) 2000-12-26 2002-10-18 Takeda Chem Ind Ltd 多孔性物質およびその製造法
US7754243B2 (en) * 2004-08-03 2010-07-13 Clemson University Research Foundation Aqueous suspension of nanoscale drug particles from supercritical fluid processing
US20060134227A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Compositions including iron
US7857977B2 (en) 2005-07-12 2010-12-28 Rockwell Medical Technologies, Inc. Packaging of ferric pyrophosphate for dialysis
ATE522151T1 (de) * 2005-07-15 2011-09-15 Unilever Nv Eisen verstärktes lebensmittel und zusatzstoff
US7816404B2 (en) * 2007-07-20 2010-10-19 Rockwell Medical Technologies, Inc. Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions
US8178709B2 (en) * 2009-07-21 2012-05-15 Biolink Life Sciences, Inc. Iron preparation suitable for pharmaceutical formulation and process for the preparation thereof
WO2012092305A2 (en) * 2010-12-27 2012-07-05 Incube Labs, Llc Nanonized iron compositions and methods of use thereof
PE20151751A1 (es) 2013-02-01 2015-12-03 Charak Llc Metodos de tratamiento de la deficiencia de hierro con pirofosfato ferrico soluble

Also Published As

Publication number Publication date
MX2018002633A (es) 2019-02-07
AU2016315877A1 (en) 2018-04-05
IL257796B (en) 2021-09-30
CL2018000566A1 (es) 2018-08-03
BR112018004244A2 (pt) 2018-09-25
CN108601738A (zh) 2018-09-28
KR20180050346A (ko) 2018-05-14
JP2018529674A (ja) 2018-10-11
PE20181162A1 (es) 2018-07-19
EP3344235A1 (en) 2018-07-11
US11517555B2 (en) 2022-12-06
US20180243256A1 (en) 2018-08-30
WO2017040937A1 (en) 2017-03-09
EA201890642A1 (ru) 2018-10-31
SG10202107245UA (en) 2021-08-30
AU2016315877B2 (en) 2022-05-26
IL257796A (en) 2018-04-30
JP7055738B2 (ja) 2022-04-18
PH12018500463A1 (en) 2018-09-17
CA2997328A1 (en) 2017-03-09

Similar Documents

Publication Publication Date Title
SV2017005555A (es) Composiciones de acido obeticolico y metodos de uso
CO2019006291A2 (es) Composiciones de aminoácidos y métodos de tratamiento de enfermedades hepáticas
SV2017005605A (es) Moduladores cot y metodos de uso de los mismos
EA201591524A1 (ru) Производные 2-аминопиримидина для лечения вирусных инфекций
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
TN2015000380A1 (en) Heterocyclic compounds and their uses
CL2015003072A1 (es) Formulaciones de liberación prolongada de colchicina y métodos de uso de las mismas.
CL2016000063A1 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
RS54584B1 (en) 15-HEPE PREPARATIONS AND PROCEDURES FOR THEIR USE
TR201909447T4 (tr) Aramkol tuzları.
CR20140175A (es) Compuestos y métodos para mejorar las respuestas inmunitarias innatas
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
MX2015012416A (es) Compuestos heterociclicos y sus usos.
CL2018001493A1 (es) Nuevos derivados de fenilo
DK2825629T3 (da) Fremstilling af docosahexaenoinsyre og/eller eicosapentaenoinsyre og/eller carotenoider i mixotrofisk tilstand under anvendelse af nitzschia
EP3377069A4 (en) PHEROMONE COMPOSITION FOR STIMULATING REPRODUCTION OF FEMALE SUIDS AND METHOD FOR USE THEREOF
DOP2017000014A (es) Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo
CL2015001446A1 (es) Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido.
CO2018002421A2 (es) Formulaciones de pirofosfato férrico sólido soluble
AR102441A1 (es) Concentrado alimenticio
MX2015016410A (es) Esteres de acidos oligo-hidroxicarboxilicos y uso de los mismos.
EA201592242A1 (ru) Производные пиридона для лечения вирусных инфекций и других заболеваний
UY37261A (es) Formulación combinada de tres compuestos antivirales
CL2017000010A1 (es) Derivados del ácido abscísico sustituido en 3'
AR097890A1 (es) Compuestos de urea